Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible participants already in active screening will be allowed to enrollTopline data from 24-week double-blind treatment
Coya Therapeutics filled all 120 spots in their medicine test for ALS. Now watch how well their drug actually works when they share results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.